News Crescita Therapeutics Inc. OTC Markets

Equities

CRRTF

CA2258471028

Market Closed - OTC Markets Other stock markets 02:14:05 2024-04-02 pm EDT			5-day change	1st Jan Change
0.32 ^USD	-0.16%		0.00%	+14.29%

Mar. 13	Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share	MT
Mar. 13	Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share	Mar. 13	MT
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	Mar. 13	CI
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Crescita Therapeutics Brief: Q4 EPS Basic and Diluted Loss $0.01	Mar. 13	MT
Crescita Reports Q4 and Fiscal 2023 Results	Mar. 13	BU
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	Nov. 08	CI
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Crescita Reports Third Quarter 2023 Results	Nov. 08	BU
Crescita Therapeutics Obtains TSX Approval for Normal Course Issuer Bid	23-08-29	MT
Crescita Therapeutics Brief: Announced Approval of Normal Course Issuer Bid	23-08-29	MT
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid	23-08-29	BU
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.	23-08-29	CI
Crescita Therapeutics Inc. authorizes a Buyback Plan.	23-08-28	CI
- Crescita Therapeutics Brief: Q2 Revenue $5.162 Million; Ending cash was $10,226, down $49 for the quarter	23-08-09	MT
Crescita Reports Second Quarter 2023 Results	23-08-09	BU
Crescita Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders	23-06-21	BU
Crescita Therapeutics Inc. Announces Launch of Topical Anaesthetic Pliaglis(R) in Europe in Its European Core Markets Including Germany, the United Kingdom and Ireland	23-06-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Crescita Therapeutics Inc. OTC Markets

Equities

CRRTF

CA2258471028

Summary

Filters